LMR Partners’s Acadia Pharmaceuticals ACAD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$3.55M Buy
+176,000
New +$4.72M 0.01% 787
2020
Q4
– Sell
-27,055
Closed -$1.12M – 480
2020
Q3
$1.12M Sell
27,055
-4,775
-15% -$206K 0.02% 200
2020
Q2
$1.54M Buy
+31,830
New +$1.53M 0.04% 298
2016
Q4
– Sell
-50,000
Closed -$1.59M – 316
2016
Q3
$1.59M Buy
50,000
+7,688
+18% +$261K 0.15% 130
2016
Q2
$1.37M Buy
+42,312
New +$1.42M 0.21% 139

Other funds holding ACAD

LMR Partners's ACAD Position: Q3 2026 in Review

LMR Partners opened a new position in Acadia Pharmaceuticals (ACAD) in Q3 2026: 176,000 shares worth $3.55M. The stake represents 0.01% of the portfolio and ranks #787 among its holdings. This is a return to the name: LMR Partners previously reported a position in ACAD as recently as Q3 2020.

LMR Partners first reported a position in ACAD in Q2 2016 and has held it in 5 quarters since. 350 funds tracked by Wall St. Rank hold ACAD as of Q3 2026.

  • LMR Partners held 176,000 shares of Acadia Pharmaceuticals worth $3.55M as of Q3 2026.
  • Acadia Pharmaceuticals was a new LMR Partners position in Q3 2026.
  • Acadia Pharmaceuticals made up 0.01% of LMR Partners's portfolio in Q3 2026, its #787 holding.
  • LMR Partners first reported a position in Acadia Pharmaceuticals in Q2 2016 and has held it in 5 quarters since.
  • 350 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2026.

Based on LMR Partners's 13F filing for Q3 2026, filed 16 Nov 2026.